Showing results (111-120 of 162) with videos related to

Sort By:
Pageof 17
Clinical & Experimental Metastasis|November 16, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2Roberta Nicoletti, Salvatore Lopez, Stefania Bellone, et al.
Gynecologic Oncology Reports|January 15, 2020
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Clinical & Experimental Metastasis|July 5, 2011
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factorEmiliano Cocco, Joyce Varughese, Natalia Buza, et al.
International Journal of Molecular Sciences|September 27, 2025
Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase InhibitorCem Demirkiran, Stefania Bellone, Victoria M Ettorre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu ExpressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Molecular Cancer Therapeutics|January 8, 2010
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201)Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, et al.
Gynecologic Oncology|August 10, 2021
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neuJoan Tymon-Rosario, Eric R Siegel, Stefania Bellone, et al.
Gynecologic Oncology|May 6, 2017
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
The Journal of Clinical Investigation|August 12, 2025
TET3 is a common epigenetic immunomodulator of pathogenic macrophagesBeibei Liu, Yangyang Dai, Zixin Wang, et al.
Virology|January 5, 2005
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapyAlessandro D Santin, Fenghuang Zhan, Eliana Bignotti, et al.
Pageof 17